HZDR is holding marketing authorizations for following PET radiopharmaceuticals

• [¹⁸F]FDG ([18F]fluoro-2-deoxy-D-glucose) - GlucoRos© since 2005
  [approval No. 63584.00.00]
• [¹⁸F]Sodium fluoride for injection - NaFRos© since 2012
  [approval No. 79232.00.00]
• [¹⁸F]FDOPA (3,4-dihydroxy-6-¹⁸F-fluoro-L-phenylalanine) – DOPARos© since 2017
  [approval No 87703.00.00]

Disposal and shipment of GlucoRos©, NaFRos© and DOPARos© is performed by our partner ROTOP Pharmaka GmbH.

The following PET radiopharmaceuticals were produced in frame of our manufacturing license for in house application

• [¹¹C]Methionin (for investigation of brain tumors and amino acid transporters)
• [¹⁸F]FMISO ([¹⁸F]Fluoromisonidazole for evaluation of tumor hypoxia)
• [¹⁸F]PSMA-1007 (a new radiotracer for prostate cancer imaging)

Additionally, HZDR is approved by GE Healthcare as manufacturing facility of

• [¹⁸F]Flutemetamol (Vizamyl©), a new radiotracer used for estimation of ß-amyloid neuritic plaque density in human brain.

Further PET radiopharmaceuticals can be provided for pre-clinical research on request

• [¹⁸F]FLT ([¹⁸F]fluorothymidine) and
• [¹⁸F]FET ([¹⁸F]fluoroethyltyrosine).